Myasthenia gravis is an autoimmune disease that causes muscle weakness, which worsens with activity and improves with rest. It affects roughly 12 people per 100,000 worldwide, with the highest rates in the Americas at about 19 per 100,000. The condition disrupts communication between nerves and muscles, making everyday actions like opening your eyes, swallowing, or lifting your arms progressively harder throughout the day.
How the Disease Affects Your Muscles
Normally, when your brain sends a signal to move a muscle, nerve endings release a chemical messenger that latches onto receptors on the muscle fiber, triggering it to contract. In myasthenia gravis, your immune system produces antibodies that attack those receptors. The antibodies work in several ways: they speed up the destruction of receptors, physically block the chemical messenger from binding, and recruit other parts of the immune system to damage the muscle surface. The result is fewer working receptors, which means nerve signals don’t reach the muscle effectively.
About 80% of people with myasthenia gravis have antibodies targeting the main receptor involved. Of the remaining 20%, roughly 7 to 10% have antibodies against a different protein that helps organize the receptor at the muscle surface. The rest may have antibodies directed at other structural proteins, though some patients test negative for all known antibodies. These different antibody types can influence how the disease behaves and which treatments work best.
What the Weakness Looks and Feels Like
The hallmark of myasthenia gravis is fatigue that builds with repeated use of a muscle and eases after rest. It doesn’t feel like general tiredness. Instead, specific muscles give out. You might start a meal chewing normally but struggle to finish because your jaw muscles weaken partway through.
The eyes are almost always involved first. Drooping eyelids and double vision are the most common early symptoms. Some people only ever have eye-related weakness, a form called ocular myasthenia gravis. In others, the disease spreads to become generalized, affecting facial muscles (creating a flat, mask-like expression), throat muscles (causing slurred speech or difficulty swallowing), neck muscles, and limbs. The weakness can fluctuate dramatically, varying in intensity over hours or days, which sometimes leads to delays in diagnosis because symptoms come and go.
How It’s Diagnosed
Blood tests for the specific antibodies are the most definitive diagnostic step. A positive result for the main receptor antibody confirms the diagnosis in most cases. When that test comes back negative, doctors check for less common antibody types. Electrical nerve studies can also reveal the characteristic pattern of weakening muscle responses during repeated stimulation.
One surprisingly simple bedside test involves placing an ice pack over a drooping eyelid for two to five minutes. Cold temperatures slow the enzyme that breaks down the nerve-to-muscle chemical messenger, temporarily boosting the signal. If the eyelid lifts at least 2 millimeters after removing the ice, the test is considered positive. Studies show this test catches about 77% of cases involving droopy eyelids, with almost no false positives. It’s quick, safe, and costs essentially nothing, making it a useful first step before blood work comes back.
Treatment Options
The first-line medication for most people works by preventing the breakdown of the chemical messenger at the nerve-muscle junction. With more messenger molecules available, the reduced number of receptors can still pick up enough signal to contract the muscle. Most people notice improvement within 30 to 60 minutes of a dose, though the effect wears off and requires repeated dosing throughout the day.
Because myasthenia gravis is an immune system problem, longer-term treatment typically involves medications that suppress or modify the immune response. These range from broadly acting immune suppressants to newer, more targeted biologic therapies. Two medications approved by the FDA in 2021 and 2023 represent a newer approach: they work by lowering levels of the harmful antibodies circulating in your blood. One reduces overall antibody levels by 60 to 70% and the specific harmful antibodies by 40 to 70% within a four-week treatment cycle. These biologics are currently approved for people with generalized myasthenia gravis who test positive for specific antibody types.
Surgical Removal of the Thymus
The thymus gland, a small organ behind your breastbone that plays a role in immune system development, is closely linked to myasthenia gravis. In many patients, the thymus is abnormally enlarged or contains a tumor called a thymoma. Surgical removal of the thymus (thymectomy) is a standard part of treatment, particularly for people with these thymus abnormalities or with the most common antibody type.
Across multiple studies, about 76% of patients who undergo thymectomy experience meaningful improvement. A landmark trial found that surgery combined with medication was more effective than medication alone at reducing symptoms, cutting the need for hospital admissions, and lowering the doses of immune-suppressing drugs over three years. In one study, nearly 44% of surgical patients achieved full remission, while another 34% saw significant improvement. About 16% experienced no change, and only 6% worsened. Younger patients and women tend to respond more favorably. Patients who still have their thymus have notably higher long-term mortality (35%) compared to those who had it removed (19%).
Myasthenic Crisis
The most dangerous complication is myasthenic crisis, where weakness of the breathing muscles becomes severe enough to require a ventilator. Infection is the most common trigger, documented in 38% of crisis episodes, with pneumonia and upper respiratory infections leading the list. Other triggers include surgery, pregnancy, temperature extremes, sleep deprivation, physical or emotional stress, and certain medications. Beta-blockers, some calcium channel blockers, several antibiotics (including certain fluoroquinolones and aminoglycosides), magnesium, and even the initial doses of corticosteroids used to treat the disease itself can provoke a crisis. In roughly one-third to one-half of cases, no obvious trigger is found.
Mortality is substantially higher among patients who experience a crisis requiring intubation. Five-year mortality in the intubated group reaches about 27%, compared to 12.5% in those who never require a ventilator. That gap persists over time, with 10-year mortality at 36% versus 18%.
Long-Term Outlook
Myasthenia gravis is a lifelong condition, but most people live well into old age with proper treatment. In a large study tracking over 400 patients, the median age at death was 80 to 81 years. Overall five-year mortality was 14%, and ten-year mortality was 21%, though these numbers include elderly patients and those with other health conditions. Mortality is highest in the first five years after symptom onset, likely reflecting the period before treatment is fully optimized and the risk window for crisis events.
Despite significant advances in biologic treatments, mortality rates have not measurably improved since the early 2000s. Researchers note that the newest therapies have only been available for a few years, and it may take more time to see their impact on survival data. What has clearly changed is quality of life: modern treatments give most patients substantially better symptom control and fewer hospitalizations than were possible even two decades ago.